These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 8987249)

  • 1. Pharmacogenetics and blood dyscrasias.
    Spielberg SP
    Eur J Haematol Suppl; 1996; 60():93-7. PubMed ID: 8987249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism.
    Spielberg SP
    J Pharmacokinet Biopharm; 1996 Oct; 24(5):509-19. PubMed ID: 9131488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relevance of pharmacogenetic aspects of mercaptopurine metabolism in the treatment of interstitial lung disease.
    Bakker JA; Drent M; Bierau J
    Curr Opin Pulm Med; 2007 Sep; 13(5):458-63. PubMed ID: 17940494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro assessment of pharmacogenetic susceptibility to toxic drug metabolites in humans.
    Spielberg SP
    Fed Proc; 1984 May; 43(8):2308-13. PubMed ID: 6714438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug metabolism and hypersensitivity reactions to drugs.
    Agúndez JA; Mayorga C; García-Martin E
    Curr Opin Allergy Clin Immunol; 2015 Aug; 15(4):277-84. PubMed ID: 26110676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thiopurine S-Methyltransferase as a Pharmacogenetic Biomarker: Significance of Testing and Review of Major Methods.
    Asadov C; Aliyeva G; Mustafayeva K
    Cardiovasc Hematol Agents Med Chem; 2017 Nov; 15(1):23-30. PubMed ID: 28552060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease.
    Chouchana L; Narjoz C; Beaune P; Loriot MA; Roblin X
    Aliment Pharmacol Ther; 2012 Jan; 35(1):15-36. PubMed ID: 22050052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on the incidence of metamizole sodium-induced blood dyscrasias in Poland.
    Basak GW; Drozd-Sokołowska J; Wiktor-Jedrzejczak W
    J Int Med Res; 2010; 38(4):1374-80. PubMed ID: 20926010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The contribution of pharmacogenetics to pharmacovigilance.
    Bondon-Guitton E; Despas F; Becquemont L
    Therapie; 2016 Apr; 71(2):223-8. PubMed ID: 27080842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity.
    Martin AM; Nolan D; Gaudieri S; Phillips E; Mallal S
    Pharmacogenomics; 2004 Sep; 5(6):643-55. PubMed ID: 15335286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-induced hypothyroidism: the thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides.
    Gupta A; Eggo MC; Uetrecht JP; Cribb AE; Daneman D; Rieder MJ; Shear NH; Cannon M; Spielberg SP
    Clin Pharmacol Ther; 1992 Jan; 51(1):56-67. PubMed ID: 1732077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics of idiosyncratic adverse drug reactions.
    Pirmohamed M
    Handb Exp Pharmacol; 2010; (196):477-91. PubMed ID: 20020273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and animal models of drug-induced blood dyscrasias.
    Ip J; Uetrecht JP
    Environ Toxicol Pharmacol; 2006 Feb; 21(2):135-40. PubMed ID: 21783650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idiosyncratic toxicity associated with potentiated sulfonamides in the dog.
    Trepanier LA
    J Vet Pharmacol Ther; 2004 Jun; 27(3):129-38. PubMed ID: 15189298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics and adverse drug reactions in the skin.
    Shear NH; Spielberg SP
    Pediatr Dermatol; 1983 Oct; 1(2):165-73. PubMed ID: 6239148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics and cutaneous drug reactions.
    Shear NH; Bhimji S
    Semin Dermatol; 1989 Sep; 8(3):219-26. PubMed ID: 2534886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenetics of drug-induced skin blistering disorders. Part I: Perspective.
    Bowman C; Delrieu O
    Pharmacogenomics; 2009 Apr; 10(4):601-21. PubMed ID: 19374517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug metabolism by leukocytes and its role in drug-induced lupus and other idiosyncratic drug reactions.
    Uetrecht J
    Crit Rev Toxicol; 1990; 20(4):213-35. PubMed ID: 2178625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Xenobiotic-metabolizing polymorphic enzymes. An opportunity for individualized drug treatment].
    Lhermitte M; Allorge D; Broly F
    Bull Acad Natl Med; 2006 Jan; 190(1):55-69; discussion 69-73. PubMed ID: 16878446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm.
    Krynetski EY; Evans WE
    Pharm Res; 1999 Mar; 16(3):342-9. PubMed ID: 10213363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.